Page 301 - Binder2

access seed platforms. And just like with generics, once the
platform is proven, scalability follows.

In this model, the roadblock isn’t factory construction. It’s
planting the next crop.

Personalization Without Price Explosion

Personalized medicine is often synonymous with rising
costs: bespoke cell therapies, AI-generated proteins,
patient-specific mRNA cocktails. But edible biologics may
offer personalization at a fraction of the price—because the
production system is biological, not mechanical.

Imagine:

• A crop of lettuce customized to a patient’s HLA
type to promote immune tolerance
• A blend of peptides designed to target your
autoantibodies, delivered daily in capsule form
• A rotation of immune-modulatory proteins tailored
to your disease cycle—planted in sequence,
harvested in sync

Because plants grow from genetic blueprints, modifying the
therapeutic payload is as simple as swapping a gene and
planting anew. No need to reconfigure a factory line or
revalidate a sterile production suite. Just grow, dry, and
dose.

This could open the door to mass-customized biologics:

299